Austar Lifesciences Limited Provided Group Earnings Guidance for the six months ending 30 June 2023. For the period, the group recorded a net loss of approximately RMB 22 million for the five months ended 31 May 2023 and is expected to record a loss attributable to the owners of the Company as compared with a profit attributable to the owners of the Company of approximately RMB 45.8 million for the six months ended 30 June 2022.